SCHEMBL1406441

SCHEMBL1406441

CN(Cc1ccccc1)c1c(-c2ccc(C(C)(C)C)cc2)cc(C(O)C#Cc2ccc(C(=O)O)cc2)cc1C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 3/20 0.42
RARG P13631 3/20 0.42
PTGES O14684 2/20 0.41
ALOX5 P09917 2/20 0.41
NR1H4 Q96RI1 5/20 0.38
RARA P10276 2/20 0.38
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
MEN1 O00255 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
RXRA P19793 3/20 0.35
RXRB P28702 3/20 0.35
RXRG P48443 1/20 0.35
NR4A2 P43354 1/20 0.34
MTTP P55157 1/20 0.34
EGFR P00533 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1406549 0.93 TAS2R14 (0.36) RARBRARGPTGESALOX5RARA
SCHEMBL1406603 0.88 RARB (0.48) RARBRARGPTGESALOX5NR1H4
SCHEMBL1406661 0.88 RARB (0.44) RARBRARGPTGESALOX5NR1H4
SCHEMBL6424171 0.86 PTGES (0.34) RARBRARGPTGESALOX5NR1H4
SCHEMBL6419793 0.86 PTGES (0.32) RARBRARGPTGESALOX5NR1H4
SCHEMBL1406741 0.83 RARB (0.42) RARBRARGPTGESALOX5NR1H4
SCHEMBL1406443 0.81 RAB9A (0.41) RARBRARGPTGESALOX5NR1H4
SCHEMBL1406372 0.81 MAP4K4 (0.36) RARBRARGRARARXRARXRB
SCHEMBL1406937 0.81 RBP4 (0.38) RARBRARGPTGESALOX5MEN1
SCHEMBL6424175 0.80 PTGES (0.32) PTGESALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP claimed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US claimed
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP disclosed
US-7468457-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-23 US disclosed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG RARB 2/4885RARG 3/4885PTGES 1620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.